Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy

Table 1 Inhibitory effect of H5B14-based ADCs on cell viability from a panel of cancer cell lines

Cancel cell lines	IC50 values of H5B14-MMAE and H5B14-DCM in cell viability (μg/ml)^a
Cancel cell lines	Zt/g4-MMAE	Zt/g4-DCM	PCM5B14-MMAE	PCM5B14-DCM	H5B14-MMAE	H5B14-DCM
MCF-7	> 100	> 100	> 100	> 100	> 100	> 100
DU4475	2.28	3.96	2.75	2.46	3.04	1.81
MDA-MB-231	6.89	3.48	5.38	5.98	6.25	5.30
T-47D	1.77	1.22	3.11	1.55	2.35	1.63
LoVo	> 100	> 100	> 100	> 100	> 100	> 100
HCT-116	2.21	0.94	3.31	1.58	2.83	1.37
HT-29	1.65	1.65	3.15	2.97	2.88	2.09
SW-620	2.97	2.65	5.44	1.92	3.35	2.95
H1993	> 100	83.89	> 100	> 100	> 100	74.07
H2228	3.86	4.28	5.63	4.65	4.49	3.64
H358	3.85	2.96	2.77	3.51	1.46	1.87
Panc-1	> 100	> 100	> 100	> 100	> 100	> 100
BxPC-3	3.04	3.89	3.25	5.25	2.68	3.02
FG	2.14	0.74	1.13	0.96	1.34	1.15
L3.6pl	1.83	2.41	2.47	4.48	3.03	1.88
Average	2.95 ± 1.52	2.61 ± 1.36	3.49 ± 1.41	3.21 ± 1.68	3.06 ± 1.36	2.43 ± 1.22

^aindividual cancer cell lines at ~ 8000 cells per well were cultured in triplicate in the presence of absence of different amounts of H5B14-MMAE or H5B14-DCM for 72 h. Zt/g4-based ADCs and PCM5B14-based ADCS were used for comparison. The MTS assay was used to determine the cell viability. The IC50 values for individual cell lines were calculated using the GraphPad Prism 7 software as previously described [1]